Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Book

Evinacumab

Neal T. Patel  1 , Mayur Parmar  2 , Preeti Patel
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan.
.
Affiliations
Free Books & Documents
Book

Evinacumab

Neal T. Patel et al.
Free Books & Documents

Excerpt

Evinacumab is a monoclonal antibody approved for adjunctive therapy for patients aged 5 years and older with homozygous familial hypercholesterolemia whose low-density lipoprotein (LDL) cholesterol remains elevated despite traditional interventions. Evinacumab is an angiopoietin-like protein 3 (ANGPTL3) inhibitor administered via intravenous infusion. This activity reviews the indications, mechanism of action, adverse reactions, contraindications, and toxicities of evinacumab and highlights the role of the interprofessional team in caring for patients with homozygous familial hypercholesterolemia and related conditions.

PubMed Disclaimer

Conflict of interest statement

Disclosure: Neal Patel declares no relevant financial relationships with ineligible companies.

Disclosure: Mayur Parmar declares no relevant financial relationships with ineligible companies.

Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.

References

    1. Krzemińska J, Młynarska E, Radzioch E, Wronka M, Rysz J, Franczyk B. Management of Familial Hypercholesterolemia with Special Emphasis on Evinacumab. Biomedicines. 2022 Dec 16;10(12) - PMC - PubMed
    1. Markham A. Evinacumab: First Approval. Drugs. 2021 Jun;81(9):1101-1105. - PubMed
    1. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet] National Institute of Diabetes and Digestive and Kidney Diseases; Bethesda (MD): 2021. Jul 8, Evinacumab.
    1. Writing Committee. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Covington AM, DePalma SM, Minissian MB, Orringer CE, Smith SC, Waring AA, Wilkins JT. 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022 Oct 04;80(14):1366-1418. - PubMed
    1. Kim K, Ginsberg HN, Choi SH. New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins. Diabetes Metab J. 2022 Jul;46(4):517-532. - PMC - PubMed

Publication types

LinkOut - more resources